Solid Biosciences Inc. Accretion (Amortization) of Discounts and Premiums, Investments
Solid Biosciences Inc. (SLDB) reported Accretion (Amortization) of Discounts and Premiums, Investments of $1.98 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments · last filed 2026-08-06
- Solid Biosciences Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2026-06-30 was $1.36M, a 179.71% increase year-over-year.
- Solid Biosciences Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2026-03-31 was $619.00K, a 98.40% increase year-over-year.
- Solid Biosciences Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2025-12-31 was $747.00K, a 6.97% decline year-over-year.
- Solid Biosciences Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2025-09-30 was $327.00K, a 72.93% decline year-over-year.
- Solid Biosciences Inc. accretion (amortization) of discounts and premiums, investments for fiscal 2025 was $1.87M, a 47.83% decline from fiscal 2024.
- Solid Biosciences Inc. accretion (amortization) of discounts and premiums, investments for fiscal 2024 was $3.59M, a 49.17% increase from fiscal 2023.
- Solid Biosciences Inc. accretion (amortization) of discounts and premiums, investments for fiscal 2023 was $2.41M.
- Solid Biosciences Inc. accretion (amortization) of discounts and premiums, investments for fiscal 2022 was -$233.00K.
| Period end | Accretion (Amortization) of Discounts and Premiums, Investments 3 month | Accretion (Amortization) of Discounts and Premiums, Investments 6 month | Accretion (Amortization) of Discounts and Premiums, Investments 9 month | Accretion (Amortization) of Discounts and Premiums, Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.98M 10-Q · filed 2026-08-06 | $2.73M derived: sum of 3 quarters · filed 2026-08-06 | $3.06M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $619.00K 10-Q · filed 2026-05-12 | $1.37M derived: sum of 2 quarters · filed 2026-05-12 | $1.69M derived: sum of 3 quarters · filed 2026-05-12 | $2.18M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $747.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.07M derived: sum of 2 quarters · filed 2026-03-19 | $1.56M derived: sum of 3 quarters · filed 2026-08-06 | $1.87M 10-K · filed 2026-03-19 |
| 2025-09-30 | $327.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $815.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.13M 10-Q · filed 2025-11-03 | $1.93M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $488.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $800.00K 10-Q · filed 2026-08-06 | $1.60M derived: sum of 3 quarters · filed 2026-08-06 | $2.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $312.00K 10-Q · filed 2026-05-12 | $1.11M derived: sum of 2 quarters · filed 2026-05-12 | $2.32M derived: sum of 3 quarters · filed 2026-05-12 | $3.36M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $803.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $2.01M derived: sum of 2 quarters · filed 2026-03-19 | $3.05M derived: sum of 3 quarters · filed 2026-03-19 | $3.59M 10-K · filed 2026-03-19 |
| 2024-09-30 | $1.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $2.25M derived: sum of 2 quarters · filed 2025-11-03 | $2.79M 10-Q · filed 2025-11-03 | $3.94M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $1.58M 10-Q · filed 2025-08-12 | $2.73M derived: sum of 3 quarters · filed 2025-08-12 | $3.72M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $540.00K 10-Q · filed 2025-05-15 | $1.69M derived: sum of 2 quarters · filed 2025-05-15 | $2.67M derived: sum of 3 quarters · filed 2025-05-15 | $2.73M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $2.13M derived: sum of 2 quarters · filed 2025-03-06 | $2.19M derived: sum of 3 quarters · filed 2025-03-06 | $2.41M 10-K · filed 2025-03-06 |
| 2023-09-30 | $984.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.04M derived: sum of 2 quarters · filed 2024-11-06 | $1.26M 10-Q · filed 2024-11-06 | $1.53M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $58.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $273.00K 10-Q · filed 2024-08-13 | $549.00K derived: sum of 3 quarters · filed 2024-08-13 | $566.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $215.00K 10-Q · filed 2024-05-15 | $491.00K derived: sum of 2 quarters · filed 2024-05-15 | $508.00K derived: sum of 3 quarters · filed 2024-05-15 | $353.00K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $276.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $293.00K derived: sum of 2 quarters · filed 2024-03-13 | $138.00K derived: sum of 3 quarters · filed 2024-03-13 | -$233.00K 10-K · filed 2024-03-13 |
| 2022-09-30 | $17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$138.00K derived: sum of 2 quarters · filed 2023-11-08 | -$509.00K 10-Q · filed 2023-11-08 | -$1.09M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-06-30 | -$155.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$526.00K 10-Q · filed 2023-08-14 | -$1.11M derived: sum of 3 quarters · filed 2024-03-13 | -$1.64M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-03-31 | -$371.00K 10-Q · filed 2023-05-11 | -$953.00K derived: sum of 2 quarters · filed 2024-03-13 | -$1.48M derived: sum of 3 quarters · filed 2024-03-13 | |
| 2021-12-31 | -$582.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$1.11M derived: sum of 2 quarters · filed 2024-03-13 | -$1.12M 10-K · filed 2024-03-13 | |
| 2021-09-30 | -$528.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$535.00K 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | -$7.00K 10-Q · filed 2022-08-11 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $0.00 derived: sum of 2 quarters · filed 2023-03-23 | -$1.00K derived: sum of 3 quarters · filed 2023-03-23 | $20.00K 10-K · filed 2023-03-23 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$1.00K derived: sum of 2 quarters · filed 2021-11-03 | $20.00K 10-Q · filed 2021-11-03 | $53.00K derived: sum of 4 quarters · filed 2022-03-14 |
| 2020-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $20.00K 10-Q · filed 2021-08-16 | $53.00K derived: sum of 3 quarters · filed 2022-03-14 | $64.00K derived: sum of 4 quarters · filed 2022-03-14 |
| 2020-03-31 | $21.00K 10-Q · filed 2021-05-14 | $54.00K derived: sum of 2 quarters · filed 2022-03-14 | $65.00K derived: sum of 3 quarters · filed 2022-03-14 | $152.00K derived: sum of 4 quarters · filed 2022-03-14 |
| 2019-12-31 | $33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $44.00K derived: sum of 2 quarters · filed 2022-03-14 | $131.00K derived: sum of 3 quarters · filed 2022-03-14 | $279.00K 10-K · filed 2022-03-14 |
| 2019-09-30 | $11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $98.00K derived: sum of 2 quarters · filed 2020-11-05 | $246.00K 10-Q · filed 2020-11-05 | $284.00K derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-06-30 | $87.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $235.00K 10-Q · filed 2020-08-06 | $273.00K derived: sum of 3 quarters · filed 2021-03-15 | $291.00K derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-03-31 | $148.00K 10-Q · filed 2020-05-07 | $186.00K derived: sum of 2 quarters · filed 2021-03-15 | $204.00K derived: sum of 3 quarters · filed 2021-03-15 | $243.00K derived: sum of 4 quarters · filed 2021-03-15 |
| 2018-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $56.00K derived: sum of 2 quarters · filed 2021-03-15 | $95.00K derived: sum of 3 quarters · filed 2021-03-15 | $90.00K 10-K · filed 2021-03-15 |
| 2018-09-30 | $18.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $57.00K derived: sum of 2 quarters · filed 2019-11-12 | $52.00K 10-Q · filed 2019-11-12 | $40.00K derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $39.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $34.00K 10-Q · filed 2019-08-14 | $22.00K derived: sum of 3 quarters · filed 2020-03-12 | -$9.00K derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | -$5.00K 10-Q · filed 2019-05-13 | -$17.00K derived: sum of 2 quarters · filed 2020-03-12 | -$48.00K derived: sum of 3 quarters · filed 2020-03-12 | -$104.00K derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | -$12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$43.00K derived: sum of 2 quarters · filed 2020-03-12 | -$99.00K derived: sum of 3 quarters · filed 2020-03-12 | -$206.00K 10-K · filed 2020-03-12 |
| 2017-09-30 | -$31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | -$87.00K derived: sum of 2 quarters · filed 2018-11-13 | -$194.00K 10-Q · filed 2018-11-13 | |
| 2017-06-30 | -$56.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | -$163.00K 10-Q · filed 2018-08-10 | ||
| 2017-03-31 | -$107.00K 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | -$505.00K 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |